ClinicalTrials.gg
Sign In
CompletedNCT00000202Updated Apr 29, 2020

Buprenorphine Maintenance for Opioid Addicts - 1

A Phase 2 interventional study of Buprenorphine in Opioid-Related Disorders, sponsored by Yale University. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-04-29.

Sponsored by Yale University · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
0
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the efficacy of buprenorphine and desipramine in treatment of opiate and cocaine dependence.

02

Conditions studied

  • Opioid-Related Disorders

Keywords

  • Opioid-Related Disorders
03

In context

Opioid-Related Disorders

1,439 studies on the registry are indexed under Opioid-Related Disorders; 291 are open to participants now.

Browse Opioid-Related Disorders studies →

Lead sponsor

Yale University is the lead sponsor of 1,763 studies on the registry; 292 are open to participants now.

Of its 217 completed or terminated interventional studies of FDA-regulated products, 128 (59%) have results posted.

Browse Yale University studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Please contact site for information.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Enrollment
0 participants

Interventions

06

Study locations

1 site
  • VA Connecticut Healthcare System
    New Haven, Connecticut 06519, United States
07

References and documents

Publications

  • J Nerv Mental Dis, 1993, 181(6) pp. 358-364; NIDA Res Mono 1993, 132:100 ; Am J Psychiatary 1993, 150:1755; Am J Addictions 1994, 3: 43-48; NIDA Res Mono 1994, 141:79; NIDA Res Mono 1995, in press.
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 1988, a primary completion of May 2006 and a completion of May 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 1999
First posted
Sep 21, 1999
Start
Aug 1988
Primary completionActual
May 2006
CompletionActual
May 2006
Last update
Apr 29, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00000202
Lead sponsor
Yale University
Collaborators
National Institute on Drug Abuse (NIDA)
Responsible party
Sponsor
First posted
Sep 21, 1999
Start date
Aug 1988
Primary completion
May 2006
Completion
May 2006
Last update
Apr 29, 2020

Study contacts

Thomas R Kosten, M.D.
principal investigator · VA Connecticut Healthcare System
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Buprenorphine

Other studies in this condition

Opioid-Related Disorders →

Other studies from this sponsor

Yale University →

Start the discussion